Emily Kaiser Maharjan

Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.

Lisa Nijm, MD, discusses how utilizing a dexamethasone intracanalicular insert after cataract surgery saves time for practices.

Preeya Gupta, MD, walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Ted Leng, MD, discusses his IRIS Registry analysis presentation regarding variations in vitreoretinal physician utilization of ancillary testing.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a triple 8 antagonist, for the treatment of dry eye.

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.

Ajay Kuriyan, MD, discusses fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting.